Orbis Medicines ApS
- Biotech or pharma, therapeutic R&D
Our mission is to define a new era for macrocycle drugs and make great contributions to medicine. We are bringing together a world-class team to make this possible.
Our broad pipeline is initially focused on delivering oral macrocycle candidates against targets validated by blockbuster biologic drugs in I&I and Cardiometabolic. The goal is to provide oral alternatives that provide meaningful value to healthcare and will enable the treatment of many more patients. In addition, we are exploring a broader variety of therapeutic areas with attractive target classes, including both intra- and extracellular targets.
Orbis has raised a total of USD 120 M from leading investors NEA, Forbion, Novo Holdings, EIFO, Cormorant, and Eli Lilly Ventures
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}